Actavis produces and markets generic, branded generic, branded and OTC pharmaceutical products globally, covering all significant therapeutic classes. Product formulations include modified release, solid oral dosage, semi-solids, suspensions, transdermals, suppositories, creams, ointments, liquids and injectables.

• Actavis Pharma: Our Actavis Pharma business markets a portfolio of more than 750 molecules offered in more than 1,700 different combinations and dosage forms.
  
• Actavis Specialty Brands: Our Actavis Specialty Brands business markets more than 40 brand pharmaceutical products, primarily in the U.S. and Canada.
  
• Biosimilars: Through both our Amgen Collaboration and our own internal development initiatives, Actavis is building a foundation for strong growth through biologics and biosimilars products

Actavis is also an established and reliable source of pharmaceutical intellectual property as our Medis third-party business is the largest out-licensing business in Europe within generics. Actavis also manufactures a range of active pharmaceutical ingredients, principally for the European and U.S. export markets.